A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients.
McCallister, Scott MD *; Valdez, Hernan MD *; Curry, Kevin MD *; MacGregor, Thomas PhD *; Borin, Marie MD +; Freimuth, William MD +; Wang, Yenyung MD +; Mayers, Douglas L. MD *
JAIDS Journal of Acquired Immune Deficiency Syndromes.
35(4):376-382, April 1, 2004.
(Format: HTML, PDF)